South Korea Restricts Gadolinium Use Over Safety Concerns
South Korea Restricts Gadolinium Use Over Safety Concerns
Introduction
Health Regulators in South Korea declared a temporary ban on Linear gadolinium agents as lawsuits against gadolinium MRI contrast dyes spike up across the U.S. The ban which will be in effect till the end of the year 2018, applies to a total of 13 linear agents, including Omniscan, Magnevist, and OptiMark informed South Korea's FDA Minister.
Though gadolinium agents are being used in MRI and MRA procedures in the United States, Canada, Japan, and Switzerland, European health regulators put a halt on the use of gadolinium agents in the brain and spinal MRI scans last year.
Gadolinium agents MultiHance and OptiMark exposure have been reported to cause brain damages and complications to other organs due to gadolinium retention inside the human body. Lawsuits filed against Linear Gadolinium-Based Contrast Agents (GBCA) claim Gadolinium Deposition Disease (GDD) and Nephrogenic Systemic Fibrosis (NSF) as potential adverse effects.
The U.S. FDA issued a black box warning about NSF for 8 MRI gadolinium agents, applicable to individuals with a pre-existing kidney disorder. Gadolinium multidistrict litigation related to NSF (MDL 1909; In Re: Gadolinium Contrast Dyes Products Liability Litigation) was created in 2008, overlooked by Judge Dan Aaron Polster in the Northern District of Ohio.
Latest News
Teen E-cigarette Use Hits 10-Year Low
Federal officials report a significant decline in teen vaping rates in the U.S., with about half a million fewer middle and high school…
Baltimore, Walgreens Reach Opioid Settlement Totaling $402.5m
The City of Baltimore has reached a settlement with Walgreens over its involvement in the opioid crisis, marking the…